20/20 Biolabs, Inc. (AIDX) SEC filings

AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 6/3063% below fair value

$0.20−0.02 (-9.38%)

Close on Nov 12, 2026Market cap $2.60MP/E –Yield –

SEC filings

17 of 20/20 Biolabs's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Proxy statement	DEF 14A	Dec 9, 2026	Oct 21, 2026	SEC EDGAR
Current report	8-K	Sep 16, 2026	Sep 18, 2026	SEC EDGAR
Current report	8-K	Sep 3, 2026	Sep 10, 2026	SEC EDGAR
Current report	8-K	Sep 2, 2026	Sep 2, 2026	SEC EDGAR
Current report	8-K	Aug 18, 2026	Aug 19, 2026	SEC EDGAR
Current report	8-K	Aug 17, 2026	Aug 17, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 14, 2026	SEC EDGAR
Current report	8-K	Aug 5, 2026	Aug 5, 2026	SEC EDGAR
Current report	8-K	Jul 16, 2026	Jul 22, 2026	SEC EDGAR
Current report	8-K	Jul 1, 2026	Jul 1, 2026	SEC EDGAR
Proxy statement	DEF 14A	Aug 18, 2026	Jun 23, 2026	SEC EDGAR
Current report	8-K	May 19, 2026	May 26, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 20, 2026	SEC EDGAR
Current report	8-K	May 20, 2026	May 20, 2026	SEC EDGAR
Current report	8-K	Apr 23, 2026	Apr 28, 2026	SEC EDGAR
Current report	8-K	Mar 31, 2026	Apr 1, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 31, 2026	SEC EDGAR

Parsed from the XBRL in 20/20 Biolabs's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AIDX.

Revenue growth16.7% · median -18.5%

Gross margin29.6% · median -10.2%

Operating margin-162.9% · median -695.7%

Net margin-182.8% · median -698.5%

Advertisement
300 × 250

See a number that looks wrong?